Sabitlenmiş Tweet
For every one time you sell for a profit and the position would have paid more if you held longer, there will be 100 that you hold too long and should have sold for a small profit. Green is green. Protect your capital.
English
AnotherWon
2.1K posts
AnotherWon
@won_another
Hope is not a trading strategy. If you’re ever looking at a position and find yourself saying, “I hope that xxxxxxx”, close it immediately. NFA.
‘Murica Katılım Eylül 2023
85 Takip Edilen67 Takipçiler
AnotherWon retweetledi
English
@Fibonacci_TA Thank you for this update, I actively look for your dark pool data 😊
English
🐋 $HIMS Dark Pool — 3-Day
Two dominant anchors. One above price, one below it. Price is sitting exactly on the lower one.
🥇 $26 → 9.5M shares (heavily DP)
🥈 $29 → 9.1M shares (almost entirely DP)
🥉 $28 → 6.1M shares (mixed)
4th: $27 → 4.1M shares (green dominant)
Last week the institutional zone was $28–$31 with 100M+ shares. Price has pulled back from that range and is now resting on $26, which absorbed nearly as much DP volume as $29 sitting overhead.
$26 is the line. Hold it and the $28–$29 cluster becomes the next magnet. Lose it and there is no meaningful DP support below.
Fibby.@Fibonacci_TA
🔥 $HIMS Flow Heatmap The May 15 column is doing two things at once. $40 calls are green while $29 puts are stacking right underneath. Near term, the flow can not agree on direction. Move to July and the picture gets cleaner — just not in a good way. The $30 strike took the biggest hit on the grid with -$459.52K in puts for July 17. That is the heaviest cell on the entire heatmap and it sits right above current price. $35 puts are building for June underneath it. The near term flow is fighting itself but the mid-term structure is stacking puts between $29 and $35. The market is not pricing in a clean breakout right now, it is pricing in a ceiling.
English
@Fibonacci_TA Frustrated by the coordinated bleeding this week is all. Even with today’s rise, which was fairly dismal compared to the overall market, it’s still sub-$28.
English
@won_another Always possible. What makes you lean that way brother?
English
🐋 $HIMS Dark Pool
The institutional zone just jumped $7 higher in one week. From $19–$21 to $28–$31.
🥇 $29 → 38.9M shares (almost entirely DP)
🥈 $28 → 38M shares (almost entirely DP)
🥉 $31 → 23.1M shares
100M+ shares across $28–$31. The old $19–$21 zone that held for weeks has been completely abandoned and ninstitutions repositioned the entire range upward. The DP dominance at $28 and $29 is extreme.
Price is trading near the lower edge of the new institutional zone. $30 adds another 19.4M and $27 holds 9.4M beneath. The volume ladder runs deep from $27 to $31.
🔑 $28–$29 with 76.9M shares combined is the new institutional core. The fastest and largest upward anchor shift we've seen on HIMS since the Novo deal.
Whether price holds in this zone or slips below $28 will determine if this was a repositioning for a new base or a distribution event on the way through.
Fibby.@Fibonacci_TA
🐋 $HIMS Whale Watch A month ago this was a bear chart. Now look at it. $30 calls at $6.3M and going vertical, $35 calls at $2.9M, $27 calls at $2.1M. Every single strike on the chart is positive except $30.50 puts at -$200K. $20M+ in total call premiums across ten strikes all building at once. This isn't one whale making a bet — this is an entire call ladder from $25 to $40 accelerating together. Whales are targeting $30-$35 with the kind of size that makes this the biggest HIMS whale flow I've ever tracked. From all-bear to the most aggressive bull positioning in the watchlist in four weeks. $6.3M on a single strike. What do they know? 👇
English
FDA in big phama’s pocket. $HIMS Ro and others will suffer bc of this. Rich get richer.
Hardik Shah@AIStockSavvy
📢 𝐉𝐔𝐒𝐓 𝐈𝐍: FDA Proposes Excluding Key GLP-1 Drugs from 503B Compounding List - $HIMS $NVO $LLY 👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ➤ FDA proposes removing 𝐬𝐞𝐦𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞, 𝐭𝐢𝐫𝐳𝐞𝐩𝐚𝐭𝐢𝐝𝐞, 𝐥𝐢𝐫𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞 from 503B list. ➤ Agency finds no sufficient 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐧𝐞𝐞𝐝 for bulk compounding. ➤ Compounding restricted unless drugs are on 𝐬𝐡𝐨𝐫𝐭𝐚𝐠𝐞 list or approved list. ➤ Move aims to protect 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐬𝐚𝐟𝐞𝐭𝐲 and regulatory integrity. ➤ FDA emphasizes use of 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 drugs over compounded alternatives. ➤ Proposal open for 𝐩𝐮𝐛𝐥𝐢𝐜 𝐜𝐨𝐦𝐦𝐞𝐧𝐭 until June 𝟐𝟗, 𝟐𝟎𝟐𝟔. ➤ Final decision pending after regulatory review process.
English
I know I know, different industries yadda yadda…just hoping that $SOFI results aren’t a preview of things to come for $HIMS ER. (1M charts of both 👇)
English
QME
@ttt_financial @aktien_max @jusifov @ball_hartwig Danke für deine Sichtweise, zum Glück ist $HIMS ja kein GLP-1 Unternehmen 😉
Deutsch
1/ Warum ich trotz Kurssturz bei $HIMS nicht gekauft habe und was mein Arzt damit zu tun hat.
Das erfahrt ihr im Video!
@topsecretstocks
@aktien_max
@jusifov
@ball_hartwig
#Börse #Aktien #hims
Thierry from arvy 🇨🇭@ThierryBorgeat
Nobody talks about the side effects of Ozempic. Wrinkles. Sunken eyes. Sagging skin. Thinner lips. The medical community calls it "Ozempic Face." Rapid fat loss doesn't just change your body. It ages your face. Millions of people are on GLP-1 drugs. Millions are now looking for the fix. That fix has a name: Sculptra. Galderma's collagen-stimulating filler restores facial volume and elasticity — directly countering what Ozempic takes away. Novo Nordisk created the problem. Galderma sells the solution. The best businesses don't just ride trends. They profit from their consequences.
Deutsch
$HIMS Down 3 straight days since this post… #JakeTheCurse
Jake Wujastyk@Jake__Wujastyk
$HIMS #HIMS Bull flag breakout on Friday.
English
$HIMS the move to $30 was textbook and hit our target with precision.
If the price now breaks and holds above $30, the next move up is $37-$40.
English
AnotherWon retweetledi
🚨 BREAKING: CANADA APPROVES FIRST GENERIC VERSION OF SEMAGLUTIDE
Indian drugmaker Dr. Reddy's application has been approved
Health Canada still reviewing 8 other submissions by different companies
$HIMS $NVO $LLY
🇨🇦🇨🇦🇨🇦
English
AnotherWon retweetledi
@arthritisfinger @TrixInvestments Aw man fuck if I know. Why not? 😂
English
@arthritisfinger @TrixInvestments Lilly partnership. It’s Tuesday after all.
English
@TrixInvestments I expect high volatility.. maybe Dudum has a little gift for us 👀 $HIMS
English
@himshouse But Andrew Dudum needs to buy am I right
English
🚨 $HIMS 2026 PROXY STATEMENT IS OUT
Insider ownership as of Apr 16:
ANDREW DUDUM: 23.8M shares (10.3%)
- 15.4M Class A + 8.4M Class V
- 87.7% of total voting power
MELISSA BAIRD (prev. COO): 1.6M shares
SOLEIL BOUGHTON (CLO): 839K shares
MIKE CHI (COO): 805K shares
YEMI OKUPE (CFO): 519K shares
MO ELSHENAWY (CTO): 283K shares
English